Glioblastoma multiforme (GBM) represents the deadliest form of brain tumour, characterized by its low survival rate and grim prognosis. Cytokines released from glioma‐associated microglia/macrophages are involved in establishing the tumour microenvironment, thereby crucially promoting GBM progression. MS4A6A polymorphism was confirmed to be associated with neurodegenerative and polymorphism disease pathobiology, but whether it participates in the regulation of GBM and the underlying mechanisms is still not elucidated. Here, we found that MS4A6A was significantly upregulated in GBM patient samples. The results from the single‐cell RNA‐sequencing (scRNA‐seq) database and immunostaining demonstrated the specific expression of MS4A6A in microglial cells. In vitro, microglial overexpression of MS4A6A stimulated the proliferation and migration of glioblastoma cells. Moreover, high MS4A6A mRNA expression was related to poor prognosis in GBM patients. Our study highlights the potential of MS4A6A as a promising biomarker for GBM, which may provide novel strategies for its prevention, diagnosis and treatment.

中文翻译：

---

小胶质细胞表达的 MS4A6A 参与胶质母细胞瘤的发病

多形性胶质母细胞瘤（GBM）是最致命的脑肿瘤，其特点是存活率低且预后严峻。神经胶质瘤相关小胶质细胞/巨噬细胞释放的细胞因子参与建立肿瘤微环境，从而至关重要地促进 GBM 进展。MS4A6A多态性被证实与神经退行性疾病和多态性疾病病理学相关，但其是否参与GBM的调节及其潜在机制仍不清楚。在这里，我们发现 MS4A6A 在 GBM 患者样本中显着上调。单细胞 RNA 测序 (scRNA-seq) 数据库和免疫染色的结果证明了 MS4A6A 在小胶质细胞中的特异性表达。在体外，小胶质细胞过度表达 MS4A6A 刺激胶质母细胞瘤细胞的增殖和迁移。而且，高MS4A6AmRNA表达与GBM患者的不良预后相关。我们的研究强调了 MS4A6A 作为 GBM 有前景的生物标志物的潜力，这可能为其预防、诊断和治疗提供新的策略。